Study to Test the Safety and Tolerability of PF-07257876 in Participants With Selected Advanced Tumors.
Public ClinicalTrials.gov record NCT04881045. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY EVALUATING THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, AND ANTITUMOR ACTIVITY OF PF-07257876 IN PATIENTS WITH ADVANCED OR METASTATIC TUMORS
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a first-in-human, Phase 1, open label, multicenter, multiple dose, dose escalation and dose expansion study intended to evaluate the safety, pharmacokinetic, pharmacodynamic and potential clinical benefit of PF-07257876, a CD47-PD-L1 bispecific antibody, in participants with selected advanced or metastatic tumors for whom no standard therapy is available. The study contains 2 parts, single agent Dose Escalation (Part 1) to determine the recommended dose of PF-07257876, followed by Dose Expansion (Part 2) in selected tumor types at the recommended dose.
Study identification
- NCT ID
- NCT04881045
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 29 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 18, 2021 (Actual)
- Primary completion
- Oct 24, 2023 (Actual)
- Completion
- Oct 24, 2023 (Actual)
- Last update posted
- Jun 2, 2026
2021 – 2023
United States locations
- U.S. sites
- 39
- U.S. states
- 12
- U.S. cities
- 28
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Mayo Clinic Hospital | Phoenix | Arizona | 85054 | — |
| Mayo Clinic | Scottsdale | Arizona | 85259 | — |
| Highlands Oncology Group | Fayetteville | Arkansas | 72703 | — |
| Highlands Oncology Group | Rogers | Arkansas | 72758 | — |
| Highlands Oncology Group | Springdale | Arkansas | 72762 | — |
| Hoag Hospital Irvine | Irvine | California | 92618 | — |
| The Angeles Clinic and Research Institute, A Cedars-Sinai Affiliate | Los Angeles | California | 90025 | — |
| Keck Hospital of USC | Los Angeles | California | 90033 | — |
| Keck School of Medicine of USC | Los Angeles | California | 90033 | — |
| LAC+USC Medical Center | Los Angeles | California | 90033 | — |
| USC/Norris Comprehensive Cancer Center | Los Angeles | California | 90033 | — |
| Hoag Memorial Hospital Presbyterian | Newport Beach | California | 92663 | — |
| Keck Hospital of USC Pasadena | Pasadena | California | 91105 | — |
| The Angeles Clinic and Research Institute, A Cedars-Sinai Affiliate (Emergency Back-Up Only) | Santa Monica | California | 90404 | — |
| Mayo Clinic Jacksonville | Jacksonville | Florida | 32224 | — |
| Mayo Clinic Rochester | Rochester | Minnesota | 55905 | — |
| Siteman Cancer Center - St Peters | City of Saint Peters | Missouri | 63376 | — |
| Siteman Cancer Center - West County | Creve Coeur | Missouri | 63141 | — |
| Siteman Cancer Center-North County | Florissant | Missouri | 63031 | — |
| Barnes-Jewish Hospital | St Louis | Missouri | 63110 | — |
| Washington University School of Medicine | St Louis | Missouri | 63110 | — |
| Washington University | St Louis | Missouri | 63110 | — |
| Siteman Cancer Center - South County | St Louis | Missouri | 63129 | — |
| Hackensack University Medical Center | Hackensack | New Jersey | 07601 | — |
| John Theurer Cancer Center at Hackensack University Medical Center | Hackensack | New Jersey | 07601 | — |
| Duke Cancer Institute | Durham | North Carolina | 27710 | — |
| UPMC Hillman Cancer Center - Camp Hill | Camp Hill | Pennsylvania | 17011 | — |
| UPMC Hillman Cancer Center - Carlisle | Carlisle | Pennsylvania | 17015 | — |
| UPMC Hillman Cancer Center Erie | Erie | Pennsylvania | 16505 | — |
| UPMC Pinnacle - Community Osteopathic / Medical Sciences Pavilion (MSP) | Harrisburg | Pennsylvania | 17109 | — |
| UPMC Pinnacle - Ortenzio Cancer Center (OCC) | Mechanicsburg | Pennsylvania | 17050 | — |
| Magee-Womens Hospital of UPMC | Pittsburgh | Pennsylvania | 15213 | — |
| UPMC Hillman Cancer Center | Pittsburgh | Pennsylvania | 15232 | — |
| UPMC Shadyside Hospital | Pittsburgh | Pennsylvania | 15232 | — |
| UPMC Memorial | York | Pennsylvania | 17408 | — |
| Rhode Island Hospital | Providence | Rhode Island | 02903 | — |
| The Miriam Hospital | Providence | Rhode Island | 02906 | — |
| Virginia Cancer Specialists | Fairfax | Virginia | 22031 | — |
| Seattle Cancer Care Alliance | Seattle | Washington | 98109 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 4 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04881045, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 2, 2026 · Synced Oct 26, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT04881045 live on ClinicalTrials.gov.